Evidence Table 61. KQ1—Dichotomous data—Composite cardiovascular outcome

| **Author Year****Study design** | **Definition of outcome (if relevant)** | **CHD risk category** | **CVD drug (dose mg/d)** | **Group 1: Supplement name (dose g/d)** | **N1** | **N1 with event** | **Group 2: Name** | **N2** | **N2 with event** | **Estimates of Group Differences** | **Additional comments** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Glynn 200725Parallel  | Combination of major cardiovascular events, includingnonfatal myocardial infarction, nonfatalstroke, and death from cardiovascular causes | Low and/or mod to high risk | ASA (100) | Vitamin E (0.1) | 9966 included | 232 | Placebo | 9968 | 245 | Crude risk ratio (95% CI): 0.95 (0.79, 1.13) P-value: 0.55 |  | Medium |